Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$55.27

1.03 (1.90%)

, CLVS

Clovis

$98.02

5.77 (6.25%)

07:08
07/31/17
07/31
07:08
07/31/17
07:08

Bristol-Myers, Clovis announce collaboration to evaluate Opdivo, Rubraca

Bristol-Myers Squibb (BMY) and Clovis Oncology (CLVS) announced the companies have entered into a clinical collaboration agreement to evaluate the combination of Bristol-Myers Squibb's immunotherapy Opdivo and Clovis Oncology's poly polymerase inhibitor Rubraca in pivotal phase 3 clinical trials in: Advanced ovarian cancer: First-line maintenance treatment study to evaluate Rubraca + Opdivo, Rubraca, Opdivo and placebo in newly diagnosed patients with stage III/IV high-grade ovarian, fallopian tube, or primary peritoneal cancer who have completed platinum-based chemotherapy. Advanced triple-negative breast cancers: First-line maintenance treatment study to evaluate Rubraca + Opdivo, Rubraca, Opdivo and chemotherapy in patients with stage IV or recurrent locally advanced inoperable TNBC associated with a homologous recombination deficiency. The collaboration will also include a Phase 2 study to evaluate the safety and efficacy of Opdivo in combination with Rubraca in patients with metastatic castration-resistant prostate cancer. The Opdivo + Rubraca combination in mCRPC will be conducted as an arm of a larger Bristol-Myers Squibb-sponsored study. The planned multi-arm clinical trials will be conducted in the U.S., Europe, and possibly additional countries. Clovis will be the study sponsor and conducting party for the ovarian cancer study and Bristol-Myers Squibb will be the study sponsor and conducting party for the breast and prostate cancer studies. Specific terms of the agreement were not disclosed. All three studies are expected to begin before the end of 2017.

BMY

Bristol-Myers

$55.27

1.03 (1.90%)

CLVS

Clovis

$98.02

5.77 (6.25%)

  • 02

    Aug

  • 11

    Sep

  • 24

    Sep

  • 09

    Nov

  • 05

    Mar

BMY Bristol-Myers
$55.27

1.03 (1.90%)

07/28/17
LEER
07/28/17
NO CHANGE
Target $61
LEER
Outperform
Bristol-Myers price target lowered to $61 after Astra trial setback at Leerink
Leerink analyst Seamus Fernandez said Bristol-Myers (BMY) reported "solid" Q2 results, including encouraging growth for its key franchises, but he sees increased uncertainty following the failure of AstraZeneca's (AZN) MYSTIC trial, which has potential read through to Bristol's CheckMate-227 trial of its I/O combo of Opdivo + Yervoy. Fernandez lowered his price target on Bristol shares to $61 from $66, but "fully acknowledges" the range of differences in the trial designs. He keeps an Outperform rating on Bristol-Myers, citing prospects for monotherapy Opdivo approval in the second-line setting and success in first-line liver cancer.
07/27/17
LEER
07/27/17
NO CHANGE
LEER
Outperform
AstraZeneca trial failure negative for Bristol-Myers, says Leerink
Leerink analyst Seamus Fernandez notes that AstraZeneca (AZN) announced that the MYSTIC trial failed to show a progression-free survival benefit for Imfinzi + tremelimumab compared to chemotherapy in first-line non-small cell lung cancer patients with PDL1 expression greater than 25%. The read through is an obvious negative readthrough for Bristol-Myers' (BMY) combo of Opdivo + Yervoy in the ongoing CheckMate-227 trial, the analyst says. He points out that while there are several key differences in trial design between MYSTIC and CM-227, they are unlikely to result in meaningfully different outcomes. Fernandez reiterates an Outperform rating on Bristol-Myers' shares.
07/27/17
GSCO
07/27/17
NO CHANGE
Target $63
GSCO
Buy
Bristol-Myers could test $50 level following MYSTIC failure, says Goldman Sachs at Goldman Sachs
Goldman analyst Jami Rubin said Bristol-Myers (BMY) could test the $50 level following the failure of AstraZeneca's MYSTIC trial as confidence gets hit for Bristol's PD-L1+CTLA4 thesis in 1L NSCLC and for its own registration phase 3 trial, CM-227, with a potential interim readout not expected till later in the year. The analyst does not have any contribution from 1L NSCLC in his estimates and note Bristol's assets and trial are very different from MYSTIC. Rubin would view any sell off on the news as a buying opportunity ahead of CM-227 optionality and or potential M&A. The analyst rates Bristol a Buy with a $63 price target.
06/27/17
06/27/17
NO CHANGE

Large cap pharma could benefit from upcoming executive order, says Wells Fargo
Wells Fargo says that, based on press reports, large cap pharma could benefit from President Trump's upcoming executive order on drug pricing. The firm says the articles indicate that the order will not create major reforms or do anything to lower consumers' costs or solve current pricing issues. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
CLVS Clovis
$98.02

5.77 (6.25%)

07/27/17
JANY
07/27/17
NO CHANGE
Target $107
JANY
Buy
PARP deals may make Clovis more attractive buyout candidate, says Janney
The partnerships announced today between AstraZeneca (AZN) and Merck (MRK) as well as Tesaro (TSRO) and Takeda highlight pharma's willingness to expand on PARP's, Janney analyst Debjit Chattopadhyay tells investors in a research note. Clovis' (CLVS) Rubraca is now the only unencumbered PARP and is "far cheaper" on a relative valuation basis than peer Tesaro, the analyst adds. He believes Clovis could now become a more compelling takeover candidate. Chattopadhyay has a Buy rating on the shares with a $107 price target. The stock in midday trading is up 7%, or $5.90, to $93.33.
07/27/17
FBCO
07/27/17
NO CHANGE
FBCO
Merck unlikely to buy PARP company after Astra deal, says Credit Suisse
Credit Suisse analyst Alethia Young believes Merck (MRK) is unlikely to acquire a PARP inhibitor company like Tesaro (TSRO) or Clovis (CLVS) after inking an immuno-oncology deal with AstraZeneca (AZN).
06/22/17
OPCO
06/22/17
INITIATION
OPCO
Perform
Clovis initiated with a Perform at Oppenheimer
Oppenheimer analyst Leah Rush Cann started Clovis with a Perform rating.
06/22/17
RHCO
06/22/17
NO CHANGE
RHCO
Clovis price target raised to $105 from $85 at SunTrust
SunTrust analyst Peter Lawson raised his price target on Clovis based on his belief that the company's PARP inhiobitor, Rubraca, showed "striking efficacy in all three cohorts" of a study. The analyst thinks that the drug will be approved in second phase and later ovarian cancer. He keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

COL

Rockwell Collins

$124.29

0.6 (0.49%)

18:36
08/22/17
08/22
18:36
08/22/17
18:36
Upgrade
Rockwell Collins rating change  »

Rockwell Collins upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$92.95

1.19 (1.30%)

18:24
08/22/17
08/22
18:24
08/22/17
18:24
Hot Stocks
Salesforce CEO says closed large deal with Veterans Administration »

Says federal government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 05

    Sep

WWR

Westwater Resources

$1.32

-0.14 (-9.59%)

18:16
08/22/17
08/22
18:16
08/22/17
18:16
Hot Stocks
Westwater Resources acquires water rights for Columbus Basin Project in Nevada »

Westwater Resources is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZTO

ZTO Express

$14.01

0.11 (0.79%)

18:03
08/22/17
08/22
18:03
08/22/17
18:03
Earnings
Breaking Earnings news story on ZTO Express »

ZTO Express sees Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

ZTO

ZTO Express

$14.01

0.11 (0.79%)

18:02
08/22/17
08/22
18:02
08/22/17
18:02
Earnings
ZTO Express reports Q2 earnings per ADS 15c, consensus 14c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

URI

United Rentals

$112.44

4.04 (3.73%)

, CMI

Cummins

$153.10

1.04 (0.68%)

17:48
08/22/17
08/22
17:48
08/22/17
17:48
Hot Stocks
United Rentals acquires power equipment assets from Cummins »

United Rentals (URI) has…

URI

United Rentals

$112.44

4.04 (3.73%)

CMI

Cummins

$153.10

1.04 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

MXIM

Maxim Integrated

$44.39

0.68 (1.56%)

, LZB

La-Z-Boy

$31.25

0.1 (0.32%)

17:40
08/22/17
08/22
17:40
08/22/17
17:40
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Maxim Integrated…

MXIM

Maxim Integrated

$44.39

0.68 (1.56%)

LZB

La-Z-Boy

$31.25

0.1 (0.32%)

CREE

Cree

$23.03

0.46 (2.04%)

VNET

21Vianet

$4.58

0.03 (0.66%)

CRM

Salesforce

$92.95

1.19 (1.30%)

RTNB

root9B Technologies

$2.98

1.72 (136.51%)

RARE

Ultragenyx

$58.85

1.94 (3.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 23

    Aug

  • 29

    Aug

  • 05

    Sep

  • 06

    Sep

  • 06

    Sep

  • 12

    Sep

  • 16

    Nov

CRM

Salesforce

$92.95

1.19 (1.30%)

17:40
08/22/17
08/22
17:40
08/22/17
17:40
Hot Stocks
Salesforce says sees FY18 margin up 125-150 bps »

Sees "slight…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 05

    Sep

MXIM

Maxim Integrated

$44.39

0.68 (1.56%)

17:34
08/22/17
08/22
17:34
08/22/17
17:34
Hot Stocks
Maxim Integrated names Sumeet Gagneja principal accounting officer »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 06

    Sep

  • 12

    Sep

CTIC

CTI BioPharma

$3.30

0.01 (0.30%)

17:33
08/22/17
08/22
17:33
08/22/17
17:33
Hot Stocks
CTI BioPharma: Chief Business Officer Matthew Plunkett resigns »

Effective August 22,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNM

Unum Group

$47.84

0.51 (1.08%)

17:32
08/22/17
08/22
17:32
08/22/17
17:32
Syndicate
Breaking Syndicate news story on Unum Group »

Unum Group files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

FTK

Flotek

$5.50

-0.1 (-1.79%)

17:29
08/22/17
08/22
17:29
08/22/17
17:29
Hot Stocks
Flotek announces conclusion of SEC inquiry »

Flotek Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 16

    May

CRM

Salesforce

$92.95

1.19 (1.30%)

17:24
08/22/17
08/22
17:24
08/22/17
17:24
Hot Stocks
Salesforce says 'had best quarter ever' »

Says can reach $20B in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 05

    Sep

THO

Thor Industries

$103.90

0.45 (0.43%)

17:17
08/22/17
08/22
17:17
08/22/17
17:17
Hot Stocks
Jayco announces expansion of Middlebury campus, will add 300 jobs »

Jayco, a subsidiary of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$924.69

18.03 (1.99%)

, GOOGL

Alphabet Class A

$940.40

19.53 (2.12%)

17:14
08/22/17
08/22
17:14
08/22/17
17:14
Hot Stocks
Google introduces Chrome Enterprise »

Google introduced Chrome…

GOOG

Alphabet

$924.69

18.03 (1.99%)

GOOGL

Alphabet Class A

$940.40

19.53 (2.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

VNET

21Vianet

$4.58

0.03 (0.66%)

17:11
08/22/17
08/22
17:11
08/22/17
17:11
Earnings
21Vianet reports Q2 EPS (12c), one estimate (11c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

RTNB

root9B Technologies

$2.98

1.72 (136.51%)

17:05
08/22/17
08/22
17:05
08/22/17
17:05
Hot Stocks
root9B Technologies announces incremental funding, status of foreclosure »

root9B Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPT

Gramercy Property Trust

$29.13

-0.03 (-0.10%)

17:03
08/22/17
08/22
17:03
08/22/17
17:03
Hot Stocks
Gramercy Property Trust launches new JV over Class A distribution centers »

Gramercy Property Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPT

Gramercy Property Trust

$29.13

-0.03 (-0.10%)

17:01
08/22/17
08/22
17:01
08/22/17
17:01
Hot Stocks
Gramercy Property Trust to acquire $479M core logistics portfolio »

Gramercy Property Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIFI

Boingo Wireless

$19.57

0.32 (1.66%)

16:55
08/22/17
08/22
16:55
08/22/17
16:55
Hot Stocks
Boingo Wireless director Michael Finley sells 7,500 shares »

Boingo Wireless director…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Sep

RTNB

root9B Technologies

$2.98

1.72 (136.51%)

16:55
08/22/17
08/22
16:55
08/22/17
16:55
Hot Stocks
Breaking Hot Stocks news story on root9B Technologies »

root9B Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTHN

Patheon

$34.96

-0.04 (-0.11%)

, TMO

Thermo Fisher

$176.79

2.78 (1.60%)

16:47
08/22/17
08/22
16:47
08/22/17
16:47
Hot Stocks
Patheon to voluntarily delist from NYSE »

Patheon (PTHN) announced…

PTHN

Patheon

$34.96

-0.04 (-0.11%)

TMO

Thermo Fisher

$176.79

2.78 (1.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

SNCR

Synchronoss

$16.71

-0.08 (-0.48%)

16:46
08/22/17
08/22
16:46
08/22/17
16:46
Hot Stocks
Synchronoss receives Nasdaq letter »

Synchronoss Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$92.95

1.19 (1.30%)

16:38
08/22/17
08/22
16:38
08/22/17
16:38
Earnings
Salesforce raises FY18 adjusted EPS view to $1.29-$1.31 from $1.28-$1.30 

FY18 consensus $1.30.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 05

    Sep

16:36
08/22/17
08/22
16:36
08/22/17
16:36
General news
API crude inventories for week of August 18 »

API reports that crude…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.